$PLSE

Teplitsky Liane Rae purchased $100K of PLSE

Teplitsky Liane Rae (Chief Operating Officer) purchased 2,025 shares of PULSE BIOSCIENCES, INC. (PLSE) at an average of $49.37 ($48.80–$49.95) across 2 trades over 2026-08-31 to 2026-09-01.

Original reporting
SEC EDGAR · Teplitsky Liane Rae
Published Sep 2, 2026, 11:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 12:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PLSE
Neutral
medium confidence
Mentioned
$PLSE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PLSENeutralLow
01

Why it matters

The COO's purchase adds a modest positive data point but is unlikely to drive trading activity.

02

Market read

Small insider purchase; limited relevance for short-term traders.

03

What to watch

Potential upcoming corporate events or financing needs not disclosed.

Relevance 4/10Novelty 4/10Timing: filing date 2026-09-02

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

$PLSENeutralMedium confidence
Context

Chief Operating Officer purchased 2,025 shares for $99,971, increasing holdings to 4,095 shares.

Expected impact

Potential slight upside pressure, unlikely to move price materially.

Evidence & confidence

The purchase is a primary Form 4 filing, providing new information, yet the dollar amount is small relative to typical market moves.

Market effects

Minimal effect on biotech sector; insider activity is routine.

None

None

Counterpoint

The purchase may be a routine compensation exercise, not a bullish signal.

Key entities

  • Teplitsky Liane Rae

    Chief Operating Officer of Pulse Biosciences, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PLSEHigh

Why is Pulse Biosciences stock surging today?

Pulse Biosciences (PLSE) stock rose 8.3% after Freedom Capital analyst Keith Hinton initiated coverage with a Buy rating and $73 price target. Hinton highlighted the company's nsPFA technology, strong balance sheet, and potential for acquisition. The NANOPULSE-AF trial is on track, with results expected in Q2 2027. Insider buying and trial progress have boosted investor confidence.

$MMEDMed

Biotech Stocks At 52-Week Highs - MMED +10%, PLSE, SOLV, RPRX, APGE

Several biotech stocks hit 52-week highs on September 1, 2026. MiniMed Group (MMED) rose 10% to $22.74 with 16.6% sales growth. Pulse Biosciences (PLSE) gained 3% to $54.39. Solventum (SOLV) reached $94.16 with 2.2% revenue growth. Royalty Pharma (RPRX) climbed to $62.58 with 14% royalty receipts growth. Apogee Therapeutics (APGE) hit $135.09 and will be acquired by AbbVie for $10.9B.

$PLSEMedAI 8/10

Pulse Biosciences (PLSE) Q2 2026 Earnings Call Transcript

Pulse Biosciences (PLSE) reported Q2 2026 revenue of $434,000 and GAAP net loss of $24.7 million. Cash and equivalents rose to $101.6 million by June 30, 2026 after $57.5 million in ATM proceeds. NANOPULSE-AF enrollment exceeded halfway with early October completion target; CE Mark for the catheter expected in 2H 2026.

$PLSEMed

PULSE BIOSCIENCES, INC. (PLSE): Results of Operations and Financial Condition

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results HAYWARD, California [Business Wire] — August 6, 2026. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-P